ZA200604070B - Composition and method - Google Patents
Composition and method Download PDFInfo
- Publication number
- ZA200604070B ZA200604070B ZA200604070A ZA200604070A ZA200604070B ZA 200604070 B ZA200604070 B ZA 200604070B ZA 200604070 A ZA200604070 A ZA 200604070A ZA 200604070 A ZA200604070 A ZA 200604070A ZA 200604070 B ZA200604070 B ZA 200604070B
- Authority
- ZA
- South Africa
- Prior art keywords
- desulfovibrio
- mixture
- tract
- group
- galactan
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 18
- 238000000034 method Methods 0.000 title claims description 9
- 241000605716 Desulfovibrio Species 0.000 claims description 32
- 241000282326 Felis catus Species 0.000 claims description 31
- 241000589989 Helicobacter Species 0.000 claims description 22
- 239000000835 fiber Substances 0.000 claims description 17
- 150000002482 oligosaccharides Chemical class 0.000 claims description 12
- 229920001542 oligosaccharide Polymers 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 8
- 229920002498 Beta-glucan Polymers 0.000 claims description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 7
- 235000013824 polyphenols Nutrition 0.000 claims description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims description 5
- 229920000189 Arabinogalactan Polymers 0.000 claims description 5
- 239000001904 Arabinogalactan Substances 0.000 claims description 5
- 235000019312 arabinogalactan Nutrition 0.000 claims description 5
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 4
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241000209219 Hordeum Species 0.000 claims 2
- 241001658044 Beata Species 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- 101150049278 US20 gene Proteins 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- 230000002550 fecal effect Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- LKDRXBCSQODPBY-VRPWFDPXSA-N D-fructopyranose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-VRPWFDPXSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 244000193510 Larix occidentalis Species 0.000 description 1
- 235000008122 Larix occidentalis Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000021238 nutrient digestion Nutrition 0.000 description 1
- 235000019895 oat fiber Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/719,569 US6936598B2 (en) | 2003-11-21 | 2003-11-21 | Composition and method |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200604070B true ZA200604070B (en) | 2007-09-26 |
Family
ID=34591365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200604070A ZA200604070B (en) | 2003-11-21 | 2006-05-19 | Composition and method |
Country Status (12)
Country | Link |
---|---|
US (1) | US6936598B2 (fr) |
EP (2) | EP1684771B1 (fr) |
JP (1) | JP4802103B2 (fr) |
CN (1) | CN100479827C (fr) |
AU (1) | AU2004292973B2 (fr) |
BR (1) | BRPI0416731A (fr) |
CA (1) | CA2545572C (fr) |
DK (1) | DK1684771T3 (fr) |
ES (1) | ES2604454T3 (fr) |
RU (1) | RU2375065C2 (fr) |
WO (1) | WO2005051403A1 (fr) |
ZA (1) | ZA200604070B (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006012536A2 (fr) | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Procedes et compositions pour le traitement de l'intolerance au lactose |
BRPI0611535B1 (pt) | 2005-05-05 | 2021-11-30 | Sensient Flavors Inc | Método para processar células de levedura para produzir beta-glucanos e mananas |
SG10201901259RA (en) | 2009-02-24 | 2019-03-28 | Ritter Pharmaceuticals Inc | Prebiotic formulations and methods of use |
EP2563372A4 (fr) | 2010-04-28 | 2013-10-02 | Ritter Pharmaceuticals Inc | Formulations prébiotiques et méthodes d'utilisation |
US20130287919A1 (en) * | 2012-04-26 | 2013-10-31 | Flavitpure, Inc. | Method of using dietary ingredients dihydroquercetin (taxifolin), arabinogalactan and arabinogalactan in combination with dihydroquercetin (taxifolin) for applications in food products |
US20130331354A1 (en) * | 2012-06-07 | 2013-12-12 | Flavitpure, Inc. | Method and composition utilizing larch wood extracts in animal feed |
US9145340B2 (en) | 2012-08-13 | 2015-09-29 | Verdesian Life Sciences, Llc | Method of reducing atmospheric ammonia in livestock and poultry containment facilities |
US9961922B2 (en) * | 2012-10-15 | 2018-05-08 | Verdesian Life Sciences, Llc | Animal feed and/or water amendments for lowering ammonia concentrations in animal excrement |
US11254620B2 (en) | 2013-08-05 | 2022-02-22 | Verdesian Life Sciences U.S., Llc | Micronutrient-enhanced polymeric seed coatings |
TW201522390A (zh) | 2013-08-27 | 2015-06-16 | 特級肥料產品公司 | 聚陰離子聚合物 |
WO2015035031A1 (fr) | 2013-09-05 | 2015-03-12 | Verdesian Life Sciences, Llc | Compositions d'acide borique |
WO2015179687A1 (fr) | 2014-05-21 | 2015-11-26 | Verdesian Life Sciences, Llc | Compositions de traitement de sol polymères comprenant des acides humiques |
CA2946202C (fr) | 2014-05-22 | 2022-06-21 | Verdesian Life Sciences, Llc | Compositions polymeres |
BR112018012966B1 (pt) * | 2015-12-30 | 2022-07-12 | Hill's Pet Nutrition, Inc | Composição de alimento para animais de estimação, seu método de formação, e uso de um componente fibroso e de uma fonte de polifenol |
CN105943463B (zh) * | 2016-06-23 | 2019-03-15 | 金日制药(中国)有限公司 | 一种温和的婴童洗发沐浴泡泡 |
US11260099B2 (en) * | 2016-12-16 | 2022-03-01 | Hills Pet Nutrition, Inc. | Pet food compositions |
US10842809B2 (en) | 2016-12-16 | 2020-11-24 | Hills Pet Nutrition, Inc. | Pet food compositions |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2549638B2 (ja) * | 1986-10-30 | 1996-10-30 | サントリー株式会社 | ビフイズス菌増殖促進組成物 |
JP2901805B2 (ja) * | 1991-05-31 | 1999-06-07 | マルハ株式会社 | ペットフード |
US5294458A (en) * | 1992-04-03 | 1994-03-15 | Maruha Corporation | Pet food |
US5444054A (en) * | 1994-04-01 | 1995-08-22 | Abbott Labatories | Method of treating ulcerative colitis |
US5614501A (en) * | 1994-07-21 | 1997-03-25 | The University Of Montana | Compositions and methods for animal husbandry and for treating gastrointestinal disorders |
US5531989A (en) * | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
US6241983B1 (en) * | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
FR2756181B1 (fr) * | 1996-11-26 | 1999-03-05 | Au Mont Beaute | Composition cosmetique, pharmaceutique a base de culture inactivee de bacteries bifidobacterium, d'huile de menthe et d'un acide |
AUPO430496A0 (en) * | 1996-12-19 | 1997-01-23 | Arnott's Biscuits Limited | Prebiotics and probiotics |
US5952033A (en) * | 1996-12-24 | 1999-09-14 | Nestec S.A. | Gelatinized cereal product containing oligosaccharide and processes of preparing and using same |
DE29724815U1 (de) * | 1997-01-09 | 2004-07-22 | Société des Produits Nestlé S.A. | Probiotik enthaltendes Getreideprodukt |
DK1003532T4 (da) * | 1997-07-05 | 2009-03-02 | Nestle Sa | Lactobacilli til fremme af tarmcellers mineralabsorption |
US6203797B1 (en) * | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
US6051260A (en) * | 1998-04-07 | 2000-04-18 | Healthcomm International, Inc. | Medical food composition of reduced allergenicity, especially adapted for improving gut mucosal integrity |
US6156355A (en) * | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
IT1304170B1 (it) * | 1998-12-15 | 2001-03-08 | Novartis Nutrition Ag | Composti organici |
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
GB9905542D0 (en) * | 1999-03-10 | 1999-05-05 | Mars Uk Ltd | Pet food |
IT1307850B1 (it) * | 1999-03-15 | 2001-11-19 | Italmed Di Galli Giovanna E Pa | Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio |
US6706287B2 (en) * | 2001-05-15 | 2004-03-16 | Kibow Biotech Inc. | Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
US6468525B1 (en) * | 1999-08-10 | 2002-10-22 | Renew Life, Inc. | Probiotic formulation |
DE10021384A1 (de) * | 2000-05-03 | 2001-11-15 | Hora Reiner | Ergänzungsfutter für Haustiere |
US20020044988A1 (en) | 2000-08-22 | 2002-04-18 | Fuchs Eileen C. | Nutritional composition and method for improving protein deposition |
FR2815823B1 (fr) * | 2000-10-31 | 2005-04-22 | Colloides Naturels Internat | Methode et preparation de type fibre alimentaire soluble bifidogene pour la mise en oeuvre de ladite methode |
US20040044988A1 (en) * | 2002-08-29 | 2004-03-04 | Schene Christopher Robin | Generation of compiled code for simulator speed up |
-
2003
- 2003-11-21 US US10/719,569 patent/US6936598B2/en not_active Expired - Lifetime
-
2004
- 2004-11-19 WO PCT/US2004/038697 patent/WO2005051403A1/fr active Application Filing
- 2004-11-19 DK DK04811413.6T patent/DK1684771T3/en active
- 2004-11-19 EP EP04811413.6A patent/EP1684771B1/fr not_active Not-in-force
- 2004-11-19 AU AU2004292973A patent/AU2004292973B2/en not_active Ceased
- 2004-11-19 CN CNB2004800344456A patent/CN100479827C/zh not_active Expired - Fee Related
- 2004-11-19 ES ES04811413.6T patent/ES2604454T3/es active Active
- 2004-11-19 JP JP2006541371A patent/JP4802103B2/ja active Active
- 2004-11-19 BR BRPI0416731-7A patent/BRPI0416731A/pt not_active Application Discontinuation
- 2004-11-19 CA CA2545572A patent/CA2545572C/fr not_active Expired - Fee Related
- 2004-11-19 EP EP16182010.5A patent/EP3111943B1/fr not_active Not-in-force
- 2004-11-19 RU RU2006121995/13A patent/RU2375065C2/ru not_active IP Right Cessation
-
2006
- 2006-05-19 ZA ZA200604070A patent/ZA200604070B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3111943B1 (fr) | 2019-06-12 |
EP3111943A1 (fr) | 2017-01-04 |
RU2375065C2 (ru) | 2009-12-10 |
US20050113334A1 (en) | 2005-05-26 |
ES2604454T3 (es) | 2017-03-07 |
EP1684771B1 (fr) | 2016-08-24 |
DK1684771T3 (en) | 2016-11-28 |
EP1684771A1 (fr) | 2006-08-02 |
JP4802103B2 (ja) | 2011-10-26 |
RU2006121995A (ru) | 2007-12-27 |
AU2004292973B2 (en) | 2010-11-25 |
WO2005051403A1 (fr) | 2005-06-09 |
AU2004292973A1 (en) | 2005-06-09 |
EP1684771A4 (fr) | 2010-07-14 |
CN100479827C (zh) | 2009-04-22 |
BRPI0416731A (pt) | 2007-01-16 |
CA2545572A1 (fr) | 2005-06-09 |
CA2545572C (fr) | 2015-02-10 |
CN1882351A (zh) | 2006-12-20 |
US6936598B2 (en) | 2005-08-30 |
JP2007512342A (ja) | 2007-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200604070B (en) | Composition and method | |
Dawood et al. | The role of β-glucan in the growth, intestinal morphometry, and immune-related gene and heat shock protein expressions of Nile tilapia (Oreochromis niloticus) under different stocking densities | |
Molist et al. | Effect of wheat bran on the health and performance of weaned pigs challenged with Escherichia coli K88+ | |
JP6514291B2 (ja) | 食事介入による胃腸の健康、免疫および働きの改善 | |
Ibrahem et al. | Effect of dietary supplementation of inulin and vitamin C on the growth, hematology, innate immunity, and resistance of Nile tilapia (Oreochromis niloticus) | |
O’doherty et al. | The effects of lactose inclusion and seaweed extract derived from Laminaria spp. on performance, digestibility of diet components and microbial populations in newly weaned pigs | |
Salem et al. | Effect of natural extracts of Salix babylonica and Leucaena leucocephala on nutrient digestibility and growth performance of lambs | |
Donalson et al. | The influence of a fructooligosaccharide prebiotic combined with alfalfa molt diets on the gastrointestinal tract fermentation, Salmonella enteritidis infection, and intestinal shedding in laying hens | |
Mair et al. | Impact of inulin and a multispecies probiotic formulation on performance, microbial ecology and concomitant fermentation patterns in newly weaned piglets | |
Hansen et al. | A high dietary concentration of inulin is necessary to reduce the incidence of swine dysentery in pigs experimentally challenged with Brachyspira hyodysenteriae | |
Hu et al. | Effects of Cu2+-exchanged montmorillonite on growth performance, microbial ecology and intestinal morphology of Nile tilapia (Oreochromis niloticus) | |
Thomsen et al. | The effect of fermentable carbohydrates on experimental swine dysentery and whip worm infections in pigs | |
CN102113619A (zh) | 一种猪用饲料防霉及霉菌毒素吸附剂 | |
Visscher et al. | Effects of feed particle size at dietary presence of added organic acids on caecal parameters and the prevalence of Salmonella in fattening pigs on farm and at slaughter | |
El-Shenawy et al. | Efficacy of zinc oxide and copper oxide nanoparticles on virulence genes of avian pathogenic E. coli (APEC) in broilers | |
Wei et al. | Inclusion of Red osier dogwood in high-forage and high-grain diets affected in vitro rumen fermentation | |
Bónai et al. | Effect of inulin supplementation and age on growth performance and digestive physiological parameters in weaned rabbits | |
Tong et al. | Effect of a prawn (Macrobrachium rosenbergii)-plant eco-symbiotic culture system (PECS) on intestinal microbiota, organic acids, and ammonia | |
MXPA06005121A (en) | Composition and method | |
Xu et al. | Effects of Cu (II)-exchanged montmorillonite on growth performance, intestinal microflora, bacterial enzyme activities and morphology of broilers | |
Al Jassim et al. | The effect of basal diet on lactate-producing bacteria and the susceptibility of sheep to lactic acidosis | |
Olszewski et al. | Cranberries (Vacciniummacrocarpon aiton) in dog nutrition: influence on diet digestibility and palatability and in the course of urinary tract infections | |
JP5222998B2 (ja) | 動物の腸管中のグラム陰性細菌コロニー形成に抗する酵素プレミックス | |
Barry | Indices of gut health and intestinal microbial ecology of the cat as affected by ingestion of select carbohydrates varying in fermentative capacity | |
Buddington et al. | The colonic bacteria and rates of small intestinal nutrient transport of mice fed diets with inulin and oligofructose |